Contineum Therapeutics, Inc. 8-K

What Happened

• On May 5, 2026 Contineum Therapeutics, Inc. issued a press release announcing the company's financial results for the quarter ended March 31, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release as Exhibit 99.1. The filing was signed by Peter Slover, Chief Financial Officer, on May 5, 2026.

Key Details

• Filing date: May 5, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the 8-K; investors should consult the exhibit for the specific revenue, net income/loss, cash position and any management commentary.
• Report signed by Peter Slover, CFO, as Principal Financial and Accounting Officer.

Why It Matters

• This 8-K notifies investors that Contineum publicly disclosed its Q1 2026 quarterly results; the details (earnings, revenue, cash and any forward guidance) are in the attached press release. Reviewing the press release is necessary to assess the company’s recent earnings performance and any implications for valuation or near-term outlook.